[go: up one dir, main page]

MX2021016034A - Compositions and methods of treating a th2-mediated condition using prevotella. - Google Patents

Compositions and methods of treating a th2-mediated condition using prevotella.

Info

Publication number
MX2021016034A
MX2021016034A MX2021016034A MX2021016034A MX2021016034A MX 2021016034 A MX2021016034 A MX 2021016034A MX 2021016034 A MX2021016034 A MX 2021016034A MX 2021016034 A MX2021016034 A MX 2021016034A MX 2021016034 A MX2021016034 A MX 2021016034A
Authority
MX
Mexico
Prior art keywords
compositions
prevotella
methods
mediated condition
treating
Prior art date
Application number
MX2021016034A
Other languages
Spanish (es)
Inventor
Holly Ponichtera
Andrea Itano
Taylor A Cormack
Kritika Ramani
Original Assignee
Evelo Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Evelo Biosciences Inc filed Critical Evelo Biosciences Inc
Publication of MX2021016034A publication Critical patent/MX2021016034A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Otolaryngology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

Provided herein are compositions and methods related to Prevotella bacteria that can be useful as therapeutic agents, for example for the treatment of a TH2-mediated condition, such as atopic dermatitis, and/or a food allergy.
MX2021016034A 2019-06-21 2020-06-18 Compositions and methods of treating a th2-mediated condition using prevotella. MX2021016034A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962864886P 2019-06-21 2019-06-21
US201962910920P 2019-10-04 2019-10-04
PCT/US2020/038335 WO2020257390A1 (en) 2019-06-21 2020-06-18 Compositions and methods of treating a th2-mediated condition using prevotella

Publications (1)

Publication Number Publication Date
MX2021016034A true MX2021016034A (en) 2022-02-21

Family

ID=71950833

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021016034A MX2021016034A (en) 2019-06-21 2020-06-18 Compositions and methods of treating a th2-mediated condition using prevotella.

Country Status (11)

Country Link
EP (1) EP3986431A1 (en)
JP (1) JP2022536861A (en)
KR (1) KR20220024684A (en)
CN (1) CN114245742A (en)
AU (1) AU2020297498A1 (en)
BR (1) BR112021025676A2 (en)
CA (1) CA3143994A1 (en)
CO (1) CO2022000278A2 (en)
MX (1) MX2021016034A (en)
TW (1) TW202120109A (en)
WO (1) WO2020257390A1 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022061119A1 (en) * 2020-09-21 2022-03-24 Evelo Biosciences, Inc. Compositions and methods for modulating immune responses with prevotella histicola
TW202227112A (en) * 2020-09-21 2022-07-16 美商艾弗洛生物科技股份有限公司 Compositions and methods of treating inflammation using prevotella histicola
JP2024505207A (en) * 2021-01-26 2024-02-05 エヴェロ バイオサイエンシズ，インコーポレーテッド Prevotella extracellular vesicle preparation
US20240148797A1 (en) * 2021-02-26 2024-05-09 Evelo Biosciences, Inc. Compositions and methods for reducing cytokine expression
WO2022187064A1 (en) * 2021-03-01 2022-09-09 Evelo Biosciences, Inc. Compositions and methods of treating inflammation using prevotella histicola
CN113509494A (en) * 2021-09-06 2021-10-19 南京医科大学 Application of prevotella in preparing medicine for treating cholestatic disease
CN114028503A (en) * 2021-12-08 2022-02-11 刘斌 Chinese and western medicine formula for treating allergic rhinitis and application
WO2023146843A1 (en) * 2022-01-25 2023-08-03 Evelo Biosciences, Inc. Extracellular vesicle compositions and methods of use
WO2023200837A1 (en) * 2022-04-13 2023-10-19 Evelo Biosciences, Inc. Compositions and methods of treating inflammation using prevotella histicola
WO2023239728A1 (en) * 2022-06-07 2023-12-14 Evelo Biosciences, Inc. Compositions and methods of treating inflammation using prevotella histicola extracellular vesicles
CN115364223A (en) * 2022-08-17 2022-11-22 郑州可尔利尔生物科技有限公司 Application of substance component acting on STAT6 target in preparation of medicine for treating chronic pruritus
KR20250056121A (en) * 2023-10-18 2025-04-25 주식회사 삼양사 Use of improvement in skin lipid composition or microflora using kestose

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8617536B2 (en) * 2009-10-30 2013-12-31 Mayo Foundation For Medical Education And Research Prevotella histicola preparations and the treatment of autoimmune conditions
CN105451576B (en) * 2013-06-03 2020-07-14 普罗普瑞弗股份公司 Treatment of obesity, metabolic syndrome, type 2 diabetes, cardiovascular disease, dementia, alzheimer's disease and inflammatory bowel disease by using at least one bacterial strain from the genus prevotella
IL277648B2 (en) * 2015-11-03 2023-04-01 Brigham & Womens Hospital Inc Therapeutic microbiota for the treatment and/or prevention of food allergy
EP3423093A4 (en) * 2016-03-04 2019-11-13 The Regents of The University of California MICROBIAL CONSORTIUM AND USES THEREOF
CN111526881A (en) * 2017-09-08 2020-08-11 伊夫罗生物科学公司 Extracellular vesicles from Prevotella

Also Published As

Publication number Publication date
TW202120109A (en) 2021-06-01
CO2022000278A2 (en) 2022-01-28
AU2020297498A1 (en) 2022-01-20
CN114245742A (en) 2022-03-25
WO2020257390A1 (en) 2020-12-24
BR112021025676A2 (en) 2022-05-17
KR20220024684A (en) 2022-03-03
EP3986431A1 (en) 2022-04-27
CA3143994A1 (en) 2020-12-24
JP2022536861A (en) 2022-08-19

Similar Documents

Publication Publication Date Title
MX2021016034A (en) Compositions and methods of treating a th2-mediated condition using prevotella.
MX2022001607A (en) Compositions and methods of treating psoriasis and atopic dermatitis using prevotella histicola.
SA520411910B1 (en) Compositions and Methods for Treating Immune Disorders Using Immune Modulating Lactococcus Bacteria Strains
MX2018011114A (en) Crispr/cas-related methods and compositions for treating beta hemoglobinopathies.
MX2022000056A (en) Stabilized anti-microbial peptides.
MX2021006581A (en) Bacteria engineered to treat diseases associated with hyperammonemia.
WO2018112365A3 (en) Methods of treating colorectal cancer and melanoma using parabacteroides goldsteinii
MX2017014020A (en) Antimicrobial therapy.
MX383448B (en) Non-aqueous topical compositions comprising a halogenated salicylanilide
CA2900779C (en) Compositions and methods for treating neurodegenerative diseases and cardiomyopathy
MX2017010150A (en) Recombinant probiotic bacteria.
WO2017136795A8 (en) Bacteria engineered to treat diseases associated with tryptophan metabolism
EP3530124A4 (en) FEED COMPOSITION WITH BACILIUS SUBTILUS STRAIN, BACILIUS PUMILUS STRAIN AND BACILIUS LICHENFORMIS STRAIN AS ACTIVE INGREDIENTS FOR THE PREVENTION OR TREATMENT OF ACUTE HEPATOPANIC NECROSIS OR WHITE-SPOT SYNDROME
WO2019040106A3 (en) Compounds, salts thereof and their use in the treatment of diseases
WO2017200873A8 (en) Compositions and methods for treating acne
MX2020006191A (en) Therapeutic bacteriocins.
WO2016200614A3 (en) Bacteria engineered to treat diseases associated with hyperammonemia
WO2017139697A8 (en) Bacteria engineered to treat diseases associated with hyperammonemia
PH12019550265A1 (en) Composition comprising mannose oligosaccharide and process for making same and use thereof
SG10201811078XA (en) Method Of Treatment Of Hypoxia Inducible Factor (HIF)-Related Conditions
SA522431538B1 (en) Methods and Compositions for the Treatment of Hair Loss
PH12020551071A1 (en) Compositions and methods for treating retinal disorders
MX2016015804A (en) Antimicrobial compositions utilizing silver and oxygen, process for making, and method of using the same.
PH12021552499A1 (en) Methods for the treatment of beta-thalassemia
PH12020551331A1 (en) Treatment and prevention of pre-eclampsia